drugset / Trial / NCT07057674

A Study of HS-20094 in Overweight or Obese Participants

NCT07057674

Phase 1 Recruiting 144 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelOther

Summary

This is a multicenter, randomized, open-label, parallel clinical study to evaluate the bioequivalence of the HS-20094 MDV pen and AI pen in overweight or obese subjects.

Timeline

Start
2025-04-16
Primary completion
2026-02-04
Completion
2026-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Olatorepatide Protein / enzyme biologic 15 mg Subcutaneous

Indications